Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...
- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited announced final approval from the U.S. Food and Drug Administration (USFDA) for its Abbrevi...
OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and...
A pivotal step in PharmaEssentia's dual-site U.S.-Taiwan manufacturing strategy, with 2027 operations in sight PharmaEssentia Corporation (TWS...
Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered c...
The partnership pairs Pillar's portfolio of oncoReveal® kitted NGS panels with CellCarta's global laboratory network and biomarker expertise to reduc...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...
Thermo Fisher Scientific Inc., the world leader in serving science, announced the global launch of the Gibco™ CTS™ Compleo™ Fill ...
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopath...
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversific...
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company w...
Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this ye...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including...
© 2026 Biopharma Boardroom. All Rights Reserved.
